~~<i id='786302BC6A'><strike id='786302BC6A'><tt id='786302BC6A'><pre id='786302BC6A'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：Wikipedia 2025-10-06 19:31:53 Page View：1839

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA panel to weigh safety of artificial wombs for preterm births
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

comprehensive

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s